The group synthesized a nanoplatform that simultaneously delivered MGLL siRNA and CB-2 siRNA to inhibit free fatty acid production in the TME and reprogramme TAMs to polarize into a tumour-inhibiting M1-like TAMs. The gene discussed is MGLL; the disease is neoplasm.